[{"id":"41954428-128f-4e4c-b4c0-e1d3824ed504","acronym":"","url":"https://clinicaltrials.gov/study/NCT02879097","created_at":"2021-01-18T14:08:01.572Z","updated_at":"2024-07-02T16:37:29.538Z","phase":"Phase 3","brief_title":"Efficacy-Safety-Immunogenicity Study of CBT124\u0026EU-sourced Avastin® in Stage 4 NSCLC","source_id_and_acronym":"NCT02879097","lead_sponsor":"Cipla BioTec Pvt. Ltd.","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR mutation • EGFR wild-type","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • EGFR wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • paclitaxel • CBT124 (bevacizumab biosimilar)"],"overall_status":"Unknown status","enrollment":" Enrollment 200","initiation":"Initiation: 12/01/2016","start_date":" 12/01/2016","primary_txt":" Primary completion: 12/01/2017","primary_completion_date":" 12/01/2017","study_txt":" Completion: 05/01/2018","study_completion_date":" 05/01/2018","last_update_posted":"2016-08-25"}]